Core Viewpoint - ST Xiangxue (300147) has been penalized by the China Securities Regulatory Commission for violations related to financial reporting and disclosure, leading to significant financial losses and ongoing legal issues [2][3][4]. Financial Reporting Violations - ST Xiangxue's 2019 annual report contained false records, with profits inflated by CNY 53.83 million, accounting for 45.98% of the reported total profit, due to unrecognized losses from the demolition of villas [2]. - The company failed to disclose non-operating fund occupation by related parties from 2016 to 2020, with amounts of CNY 585 million, CNY 844.85 million, CNY 1.408 billion, CNY 656.97 million, and CNY 1.356 billion respectively, which were significant omissions in annual reports [2]. Financial Performance - In 2024, ST Xiangxue reported a revenue of CNY 1.858 billion, a decrease of 19.16% year-on-year, and a net loss of CNY 858.56 million, down 120.73% compared to the previous year [4][5]. - The net cash flow from operating activities was CNY 18.17 million, a decline of 93.10% from the previous year [5]. Legal Issues - As of July 17, the company and its subsidiaries were involved in lawsuits with a total amount of approximately CNY 223.43 million, representing 21.18% of the latest audited net assets [4][6]. - The lawsuits include financial lending disputes and engineering contract disputes, with various amounts claimed by different parties [4][6].

Core Viewpoint - Guangzhou Xiangxue Pharmaceutical Co., Ltd. (referred to as "Xiangxue Pharmaceutical" or "ST Xiangxue") has been penalized for information disclosure violations, receiving a total fine of 16 million yuan, raising concerns about its future recovery from this situation [1][5]. Group 1: Regulatory Actions and Penalties - The Guangdong Regulatory Bureau has issued a warning and imposed a fine of 6 million yuan on Xiangxue Pharmaceutical for failing to disclose losses from the demolition of villas and for significant omissions in its annual reports [1][3]. - The actual controller, Wang Yonghui, has been fined 10 million yuan, with 3 million yuan as a direct responsible supervisor and 7 million yuan as the actual controller [1][5]. - Xiangxue Pharmaceutical plans to apply for the removal of risk warnings on its stock after 12 months from the issuance of the administrative penalty decision [1]. Group 2: Financial Performance and Historical Context - Xiangxue Pharmaceutical's net profit peaked at over 100 million yuan after its market debut in 2010, but it began to decline in 2016, with a net profit drop of over 60% to 66.02 million yuan [6]. - From 2016 to 2020, the company's net profit remained between 60 million and 70 million yuan, but it reported a loss of 677 million yuan in 2021 due to intensified market competition and asset impairment [6]. - The company continued to incur losses in 2022, 2023, and 2024, with losses of 530 million yuan, 389 million yuan, and 859 million yuan respectively, and a significant decline in revenue of 25.99% in Q1 2024 [7]. Group 3: Legal and Operational Challenges - Xiangxue Pharmaceutical has faced multiple lawsuits, with a total amount involved of approximately 223 million yuan, which is 21.18% of its latest audited net assets [7]. - The company has not responded to inquiries regarding its corrective measures following the administrative penalty and its strategies to balance compliance and operational efficiency [8].

Group 1 - The company experienced a significant stock price fluctuation, with a cumulative deviation of 35.11% over two consecutive trading days on August 18 and 19, 2025, indicating abnormal trading activity [1] - The company's board of directors conducted inquiries with major stakeholders, including the controlling shareholder and senior management, confirming no undisclosed significant information affecting stock trading [1][2] - The company has not disclosed any major matters related to its pre-restructuring process that have not been previously reported, ensuring compliance with relevant regulations [2][3] Group 2 - The company is currently undergoing a pre-restructuring process, which is a preliminary step before formal restructuring, and the outcome remains uncertain [3] - If the restructuring is successful, it could improve the company's financial structure and sustainability; however, failure could lead to bankruptcy and delisting risks [3]

Core Viewpoint - The avian influenza concept sector has seen a significant increase, with a rise of 2.45%, ranking third among concept sectors on the trading day ending August 19. Group 1: Sector Performance - The avian influenza sector had 18 stocks rising, with ST Xiangxue hitting a 20% limit up, and Kangyuan Pharmaceutical also reaching the limit up. Other notable gainers included Yongshun Biological, Lianhuan Pharmaceutical, and Zhongsheng Pharmaceutical, which rose by 9.35%, 6.08%, and 3.79% respectively [1] - The top-performing concept sectors included: - Reducer: +2.62% - Animal Vaccine: +2.47% - Avian Influenza: +2.45% [1] Group 2: Capital Flow - The avian influenza sector attracted a net inflow of 109 million yuan, with 15 stocks receiving net inflows. Five stocks had net inflows exceeding 10 million yuan, led by Kangyuan Pharmaceutical with a net inflow of 154 million yuan [1] - The top stocks by net capital inflow ratio included: - Kangyuan Pharmaceutical: 19.87% - ST Xiangxue: 14.18% - Zhongmu Stock: 5.23% [2]

证券代码:300147 证券简称: ST 香雪 公告编号:2025-039 广州市香雪制药股份有限公司 股票交易异常波动的公告 6、公司于2025年2月6日披露了《关于被债权人申预请重整的提示性公告》 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况 广州市香雪制药股份有限公司（以下简称"公司"）于2025年8月18日、8 月19日连续两个交易日收盘价格偏离值累计达到35.11%，根据《深圳证券交易所 交易规则》的有关规定，属于股票交易异常波动的情形。敬请广大投资者注意交 易风险，理性决策，审慎投资。 二、公司关注并核实情况 针对公司股票交易异常波动的情况，公司董事会通过电话及现场问询的方式， 对公司控股股东及实际控制人、公司全体董事、监事及高级管理人员就相关问题 进行了核实，现就相关情况说明如下： 1、公司前期披露的信息不存在需要更正、补充之处。 2、截至本公告披露日，公司、控股股东及实际控制人不存在关于公司的应 披露而未披露的重大事项。 3、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较 大影响的未公开重大信息。 ...

证券之星消息，8月19日中药板块较上一交易日上涨0.57%，ST香雪领涨。当日上证指数报收于3727.29， 下跌0.02%。深证成指报收于11821.63，下跌0.12%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300147 | ST香雪 | 10.54 | 20.05% | 66.89万 | | 6.52亿 | | 600594 | 益僧制药 | 4.59 | 10.07% | 42.52万 | | 1.89亿 | | 603139 | 康惠制药 | 25.18 | 10.00% | 3.83万 | | 9369.95万 | | 002873 | 新天药业 | 15.19 | 9.99% | 1 29.29万 | | 4.38亿 | | 600557 | 康家药业 | 19.83 | 9.98% | 39.16万 | | 7.74亿 | | 600671 | 天目药业 | 16.89 | 6.03% | 9.59万 | | 1.58亿 | | ...

Market Overview - The Shanghai Composite Index closed at 3739.26 points, above the annual line, with a change of 0.30% [1] - The total trading volume of A-shares reached 16780.81 billion yuan [1] Stocks Breaking Annual Line - A total of 38 A-shares have broken above the annual line today, with notable stocks including Chengmai Technology, ST Xiangxue, and Huali Co., with deviation rates of 19.19%, 11.40%, and 4.94% respectively [1] - Stocks with smaller deviation rates that just crossed the annual line include Hangzhou Thermal Power, ShuiJinFang, and Jian Design [1] Top Stocks by Deviation Rate - Chengmai Technology (300598) saw a price increase of 20.00% with a turnover rate of 15.15%, latest price at 55.39 yuan, deviation rate of 19.19% [1] - ST Xiangxue (300147) increased by 15.83% with a turnover rate of 7.20%, latest price at 10.17 yuan, deviation rate of 11.40% [1] - Huali Co. (603038) rose by 7.34% with a turnover rate of 8.87%, latest price at 15.51 yuan, deviation rate of 4.94% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include *ST Xinyuan (300472) with a 6.57% increase and a deviation rate of 4.21% [1] - Jiutian Pharmaceutical (300705) increased by 3.77% with a deviation rate of 3.57% [1] - Guodian Power (600795) rose by 5.10% with a deviation rate of 3.54% [1]

Market Performance - As of August 18, the Shanghai Composite Index closed at 3728.03 points, with a change of +0.85% [1] - The Shenzhen Component Index closed at 11835.57 points, with a change of +1.73% [1] - The ChiNext Index closed at 2606.20 points, with a change of +2.84% [1] Trading Volume Analysis - A total of 3145 stocks saw an increase in average transaction volume, with 69 stocks experiencing an increase of over 50% [1] - Notable stocks with significant increases in average transaction volume include Hengshen New Materials (+230.41%), Changyuan Donggu (+166.68%), and Furuide (+166.49%) [1] - Conversely, 1407 stocks experienced a decrease in average transaction volume [1] Active Stocks by Transaction Count - The stocks with the highest increase in transaction count include Quzhou Development (+6673.62%), Huakong Saige (+585.39%), and Guanshi Technology (+563.59%) [2] - Other notable stocks with significant increases in transaction count are ST Xiangxue (+557.96%) and Shangrong Medical (+554.81%) [2] Stocks with Both Volume and Count Increases - City Media reported a daily change of +7.24%, with both average transaction volume and transaction count increasing by over 50% [3] - Huazhi Digital Media showed a daily change of +20.02%, with a significant increase in transaction count by +469.66% [4] - Other stocks with notable increases in both metrics include Yunnan Energy Investment (+9.98%) and Tianchuang Fashion (+1.94%) [4]

Market Overview - The Shanghai Composite Index closed at 3740.50 points, above the six-month moving average, with an increase of 1.18% [1] - The total trading volume of A-shares reached 17,467.28 million yuan [1] Stocks Breaking the Six-Month Moving Average - A total of 187 A-shares have surpassed the six-month moving average today [1] - Notable stocks with significant deviation rates include: - Jingsai Technology (27.02%) - Haidaer (25.37%) - Huazhi Shumedia (16.28%) [1] Stocks with Smaller Deviation Rates - Stocks that have just crossed the six-month moving average with smaller deviation rates include: - Tianfang Biao - Anning Co. - Tianwei Foods [1] Performance of Selected Stocks - Jingsai Technology: Today's increase of 29.98%, turnover rate of 23.53%, six-month average price of 36.65 yuan, latest price of 46.56 yuan [1] - Haidaer: Today's increase of 30.00%, turnover rate of 24.95%, six-month average price of 47.67 yuan, latest price of 59.76 yuan [1] - Huazhi Shumedia: Today's increase of 20.02%, turnover rate of 8.50%, six-month average price of 9.95 yuan, latest price of 11.57 yuan [1]

Core Viewpoint - Xiangxue Pharmaceutical (300147.SZ) is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, resulting in an administrative penalty [1] Summary by Relevant Categories Company Penalties - The company has been ordered to rectify its actions and received a warning, along with a fine of 6 million yuan [1] - The actual controller and former chairman, Wang Yonghui, was fined 10 million yuan, which includes 3 million yuan as the directly responsible supervisor and 7 million yuan as the actual controller [1] - The former CFO, Lu Feng, received a warning and a fine of 2 million yuan [1] Other Executive Penalties - Former directors and executives Huang Bin and Xu Li were each warned and fined 1 million yuan [1] - Former CFO Chen Binghua was warned and fined 150,000 yuan [1]